BACKGROUND: Results of a multicenter, randomized, clinical trial demonstrated that @entity1140 was more effective than @entity205 in preventing acute rejection in cadaveric renal transplant @entity1 . As African-Americans comprised approximately 25% of the study population, their outcome was analyzed relative to the experience of Caucasian @entity1 . METHODS: Of the 205 @entity1 randomized to @entity1140 , 56 (27.3%) were African-American and 114 (55.6%) were Caucasian. Of the 207 @entity1 randomized to @entity205 , 48 (23.2%) were African-American and 123 (59.4%) were Caucasian. The efficacy variables were 1-year @entity1 survival, graft survival, and incidence of acute rejection. RESULTS: The incidence of acute rejection was significantly lower in African-American and Caucasian @entity1 treated with @entity1140 than with @entity205 . Additionally, no African-American @entity1 who was treated with @entity1140 experienced moderate or severe acute rejection, as determined by blinded independent review. The incidence of nephrotoxicity, cardiovascular and gastrointestinal events, @entity5 , and @entity1292 was similar between treatments and race groups. However, there was an increased incidence of @entity6 in @entity1140 -treated @entity1 , particularly in African-Americans, and @entity1140 was associated with significantly lower lipid levels in both Caucasians and African-Americans. African-American @entity1 required a 37% mean higher dose of @entity1140 than Caucasian @entity1 to achieve comparable blood concentrations. CONCLUSIONS: @entity1140 is more effective than @entity205 in preventing acute rejection in both African-American and Caucasian @entity1 . However, @entity1140 was associated with an increased risk of @entity6 , particularly in African-Americans, which was reversible in some @entity1 .

Racial differences in renal transplantation after immunosuppression with XXXX versus @entity205 . @entity1140 Kidney Transplant Study Group.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6 :: ('MESH:D003920', 'Disease') :: ['posttransplant diabetes mellitus'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus'] @entity1292 :: ('MESH:D009894', 'Disease') :: ['opportunistic infections']
@entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']
